----
Current ValuationThe current P/E ratio is -5.14, within the reasonable range, cheaper than 30.1% of the time in the past 3 years, and the industry ranks 385/605, the industry Median -1.91.
-5.14xP/E
$1.43Stock price
$-0.28Earnings per share
-5.14xP/E
Stock price$1.43Earnings per share$-0.28
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -7.94x
- Typical range
- -12.95x–-3.30x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
021426384
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -60.16x | 150.60% | $194.91B |
MRNAUSModerna | -25.67x | 17.00% | $80.90B |
CSLLYUSCSL Limited | -25.55x | -- | $65.90B |
NTRAUSNatera | -300.79x | 5.57% | $57.86B |
RVMDUSRevolution Medicines | -22.75x | 61.94% | $40.23B |
ROIVUSRoivant Sciences | -101.60x | 146.69% | $27.05B |
BNTXUSBioNTech SE | -11.52x | 19.30% | $22.53B |
INSMUSInsmed | -23.72x | 75.01% | $20.76B |
BBIOUSBridgebio Pharma | -19.25x | 28.60% | $13.32B |
SMMTUSSummit Therapeutics | -14.49x | 19.79% | $12.41B |
MDGLUSMadrigal Pharma | -32.22x | 51.30% | $10.47B |
PCVXUSVaxcyte | -9.29x | 47.91% | $9.89B |
KYMRUSKymera Therapeutics | -30.77x | 5.24% | $9.22B |
TWSTUSTwist Bioscience | -65.23x | 28.71% | $8.92B |
IBRXUSImmunityBio | -8.88x | 151.32% | $8.81B |
CYTKUSCytokinetics | -9.69x | 6.85% | $8.67B |
ARWRUSArrowHead Pharma | -25.76x | 35,923.70% | $8.24B |
SYREUSSpyre Therapeutics | -54.20x | 45.60% | $8.14B |
ABVXUSAbivax SA | -16.91x | 22.99% | $7.87B |
IONSUSIonis Pharma | -12.91x | 49.51% | $7.30B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
